Literature DB >> 29158287

Development of a Premium Quality Plasma-derived IVIg (IQYMUNE®) Utilizing the Principles of Quality by Design-A Worked-through Case Study.

Philippe Paolantonacci1, Philippe Appourchaux1, Béatrice Claudel1, Monique Ollivier1, Richard Dennett1, Laurent Siret2.   

Abstract

Polyvalent human normal immunoglobulins for intravenous use (IVIg), indicated for rare and often severe diseases, are complex plasma-derived protein preparations. A quality by design approach has been used to develop the Laboratoire Français du Fractionnement et des Biotechnologies new-generation IVIg, targeting a high level of purity to generate an enhanced safety profile while maintaining a high level of efficacy. A modular approach of quality by design was implemented consisting of five consecutive steps to cover all the stages from the product design to the final product control strategy.A well-defined target product profile was translated into 27 product quality attributes that formed the basis of the process design. In parallel, a product risk analysis was conducted and identified 19 critical quality attributes among the product quality attributes. Process risk analysis was carried out to establish the links between process parameters and critical quality attributes. Twelve critical steps were identified, and for each of these steps a risk mitigation plan was established.Among the different process risk mitigation exercises, five process robustness studies were conducted at qualified small scale with a design of experiment approach. For each process step, critical process parameters were identified and, for each critical process parameter, proven acceptable ranges were established. The quality risk management and risk mitigation outputs, including verification of proven acceptable ranges, were used to design the process verification exercise at industrial scale.Finally, the control strategy was established using a mix, or hybrid, of the traditional approach plus elements of the quality by design enhanced approach, as illustrated, to more robustly assign material and process controls and in order to securely meet product specifications.The advantages of this quality by design approach were improved process knowledge for industrial design and process validation and a clear justification of the process and product specifications as a basis for control strategy and future comparability exercises. © PDA, Inc. 2018.

Entities:  

Keywords:  CLAIRYG®; IQYMUNE®; Intravenous immunoglobulins; Polyvalent human normal immunoglobulins; Quality by design; Quality risk management

Mesh:

Substances:

Year:  2017        PMID: 29158287     DOI: 10.5731/pdajpst.2016.007393

Source DB:  PubMed          Journal:  PDA J Pharm Sci Technol        ISSN: 1079-7440


  1 in total

1.  An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study.

Authors:  Eduardo Nobile-Orazio; Sonia Pujol; Fabrice Kasiborski; Rabye Ouaja; Gilles Della Corte; Robert Bonek; Dario Cocito; Angelo Schenone
Journal:  J Peripher Nerv Syst       Date:  2020-08-31       Impact factor: 3.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.